[go: up one dir, main page]

PT3088353T - Partículas de bilirrubina e sua preparação para utilização em terapia - Google Patents

Partículas de bilirrubina e sua preparação para utilização em terapia

Info

Publication number
PT3088353T
PT3088353T PT148753494T PT14875349T PT3088353T PT 3088353 T PT3088353 T PT 3088353T PT 148753494 T PT148753494 T PT 148753494T PT 14875349 T PT14875349 T PT 14875349T PT 3088353 T PT3088353 T PT 3088353T
Authority
PT
Portugal
Prior art keywords
preparation
method therefor
bilirubin nanoparticle
bilirubin
nanoparticle
Prior art date
Application number
PT148753494T
Other languages
English (en)
Original Assignee
Korea Advanced Inst Sci & Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Advanced Inst Sci & Tech filed Critical Korea Advanced Inst Sci & Tech
Publication of PT3088353T publication Critical patent/PT3088353T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT148753494T 2013-12-27 2014-12-26 Partículas de bilirrubina e sua preparação para utilização em terapia PT3088353T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130165718 2013-12-27

Publications (1)

Publication Number Publication Date
PT3088353T true PT3088353T (pt) 2020-02-24

Family

ID=53479252

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148753494T PT3088353T (pt) 2013-12-27 2014-12-26 Partículas de bilirrubina e sua preparação para utilização em terapia

Country Status (10)

Country Link
US (2) US11904019B2 (pt)
EP (1) EP3088353B8 (pt)
KR (1) KR101681299B1 (pt)
DK (1) DK3088353T3 (pt)
ES (1) ES2774035T3 (pt)
HR (1) HRP20200256T1 (pt)
HU (1) HUE047912T2 (pt)
PL (1) PL3088353T3 (pt)
PT (1) PT3088353T (pt)
WO (1) WO2015099492A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015099492A1 (ko) * 2013-12-27 2015-07-02 한국과학기술원 빌리루빈 나노입자, 이의 용도 및 제조방법
KR102254093B1 (ko) * 2017-05-12 2021-05-20 주식회사 빌릭스 빌리루빈 유도체 및 금속을 포함하는 입자
KR102056948B1 (ko) * 2018-02-05 2019-12-17 주식회사 빌릭스 빌리루빈 유도체 기반의 진단 및 치료용 초음파 조영제
CN110898228B (zh) * 2018-09-17 2022-10-04 天津大学 肿瘤自靶向光致异构纳米载体及其制备方法
US20220127528A1 (en) * 2019-01-22 2022-04-28 Purdue Research Foundation Bilirubin-coated radio-luminescent particles
US20220142980A1 (en) * 2019-02-25 2022-05-12 The University Of Toledo Pegylated bilirubin for the treatment of hyperlipidemia, obesity, fatty liver disease, cardiovascular diseases and type ii diabetes
CN112618730A (zh) * 2019-09-24 2021-04-09 天津大学 一种活性氧响应性纳米药物-基因共递送体系及其制备方法
CN112023060B (zh) * 2020-09-16 2023-06-13 上海市第一人民医院 一种靶向软骨具光热响应特征的双药负载纳米微球及其制备方法和应用
KR102591787B1 (ko) * 2021-01-13 2023-10-20 한국과학기술원 키토산-빌리루빈 접합체를 포함하는 입자 및 이를 포함하는 약제학적 조성물
CN112972392B (zh) * 2021-03-10 2022-06-21 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) 一种胆红素纳米颗粒及其制备和应用
CN115317437B (zh) * 2021-05-11 2023-09-08 中国科学院上海硅酸盐研究所 一种基于胆红素纳米材料的胰岛素递送微针及其制备方法
US20240327345A1 (en) 2021-08-11 2024-10-03 Bilix Co., Ltd. Method for synthesizing bilirubin
KR102553484B1 (ko) 2021-08-11 2023-07-10 주식회사 빌릭스 빌리루빈의 합성 방법
CN117836290A (zh) 2021-08-11 2024-04-05 株式会社毕丽斯 胆红素的合成方法
WO2023018215A1 (ko) 2021-08-11 2023-02-16 주식회사 빌릭스 빌리루빈의 합성 방법
EP4375280A4 (en) 2021-08-11 2025-01-08 Bilix Co., Ltd. Method for synthesizing bilirubin
WO2023018217A1 (ko) 2021-08-11 2023-02-16 주식회사 빌릭스 빌리루빈의 합성 방법
CN114767839B (zh) * 2021-10-28 2024-07-02 上海巴久巴生物技术有限公司 一种纳米复合物及应用
CN114181286A (zh) * 2021-11-01 2022-03-15 清华大学 一种纳米蛋白复合物、药物递送系统及应用
CN119403553A (zh) * 2022-07-05 2025-02-07 株式会社毕丽斯 包含聚乙二醇化胆红素的用于预防或治疗炎性疾病的药物组合物
CN116370501B (zh) * 2023-03-08 2025-06-27 温州医科大学 一种复合纳米颗粒及其在制备治疗糖尿病的药物中的用途
CN116492286B (zh) * 2023-04-04 2025-08-22 重庆医科大学附属口腔医院 一种载近红外响应性复合胆红素纳米颗粒的牙周微针及其制备方法
CN117100856A (zh) * 2023-08-03 2023-11-24 广州医科大学 光敏化合物在制备trpa1光通道作为靶点的产品中的应用
CN117016537A (zh) * 2023-09-04 2023-11-10 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) 一种褪黑素纳米颗粒及其制备方法和用途
KR20250128235A (ko) 2024-02-20 2025-08-27 주식회사 심비스타 Nmda 수용체 항체 및 형광물질을 포함하는 신규 테라그노스틱 나노복합체 및 이것의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US6916488B1 (en) 1999-11-05 2005-07-12 Biocure, Inc. Amphiphilic polymeric vesicles
GB0004549D0 (en) * 2000-02-25 2000-04-19 Isis Innovation Degradation fragments
WO2003037295A2 (en) * 2001-11-02 2003-05-08 The Governors Of The University Of Alberta Micelle compositions containing pegylated phospholipids and a photosensitizer
DE10331439B3 (de) * 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20070032842A1 (en) * 2005-08-03 2007-02-08 Strong Nathan R Phototherapy Device for Treating Hyperbilirubinemia
KR20080095130A (ko) * 2007-04-23 2008-10-28 한국과학기술연구원 pH 민감성 블록공중합체를 이용한 약물전달체 제조 및응용
WO2009061406A1 (en) * 2007-11-05 2009-05-14 The Trustees Of Princeton University Nanoparticles for photodynamic therapy
EP2346515A4 (en) * 2008-09-25 2013-01-23 Invivo Therapeutics Corp SPINAL CORD INJURY, INFLAMMATION AND IMMUNE DISEASE: CONTROLLED LOCAL RELEASE OF THERAPEUTIC AGENTS
JP5849947B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
EP2713747B1 (en) * 2011-05-24 2023-02-22 Agienic, Inc. Compositions and methods for antimicrobial metal nanoparticles
US20130345614A1 (en) * 2012-06-22 2013-12-26 Viraj P. Mane Device for extracorporeal photo-isomerization for hyperbilirubinemia, and method thereof
WO2015099492A1 (ko) * 2013-12-27 2015-07-02 한국과학기술원 빌리루빈 나노입자, 이의 용도 및 제조방법
KR102254093B1 (ko) * 2017-05-12 2021-05-20 주식회사 빌릭스 빌리루빈 유도체 및 금속을 포함하는 입자
KR102056948B1 (ko) * 2018-02-05 2019-12-17 주식회사 빌릭스 빌리루빈 유도체 기반의 진단 및 치료용 초음파 조영제

Also Published As

Publication number Publication date
EP3088353A1 (en) 2016-11-02
DK3088353T3 (da) 2020-02-24
US20240082408A1 (en) 2024-03-14
PL3088353T3 (pl) 2020-07-13
EP3088353A4 (en) 2016-12-28
HUE047912T2 (hu) 2020-05-28
US20170028076A1 (en) 2017-02-02
ES2774035T3 (es) 2020-07-16
HRP20200256T1 (hr) 2020-11-13
KR20150079436A (ko) 2015-07-08
US11904019B2 (en) 2024-02-20
KR101681299B1 (ko) 2016-12-05
WO2015099492A1 (ko) 2015-07-02
EP3088353B8 (en) 2020-04-08
EP3088353B1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
PT3088353T (pt) Partículas de bilirrubina e sua preparação para utilização em terapia
IL240475A0 (en) Tubulin compounds, methods for their preparation and use
ZA201506216B (en) Phototherapeutic device, method and use
EP3026891A4 (en) Imaging element, imaging method, and program
SG10201710610PA (en) Etching agent, etching method and etching agent preparation liquid
GB201319878D0 (en) Method, Array and use thereof
EP3065712A4 (en) Microparticles, methods for their preparation and use
EP2961478A4 (en) Phototherapeutic device, method and use
EP3032307A4 (en) Imaging device, imaging method and program
EP3040754A4 (en) Imaging device, method, and program
EP3085797A4 (en) Alloy for medical use, and method for producing same
IL243699A0 (en) Benzoxaborole-type substances, a process for their preparation and preparations containing them
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
EP2950646A4 (en) AGROCHEMICAL COMPOSITION, PROCESS FOR PREPARATION AND USE THEREOF
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
PL3033532T3 (pl) Element łączący, zastosowanie i sposób
EP2952519A4 (en) PROTOPANOXADIOL DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
EP3041217A4 (en) Imaging device, method and program
EP3006432A4 (en) 2,3-BANDEDIAMIDE EPOXY COMPOUND AND METHOD OF MANUFACTURE AND USE THEREOF
ZA201603990B (en) Taxane compound, and preparation method and use thereof
EP2980096A4 (en) 2,3,5-trihydroxy-androst-6-one, as well as method of preparation and use thereof
ZA201603682B (en) Taxanes compounds, preparation method therefor, and uses thereof
GB2513859B (en) Agrochemical composition, method for its preparation and the use thereof
GB2550089B (en) Agrochemical composition, method for its preparation and the use thereof
HUE032883T2 (hu) Poliolok, elõállításuk és alkalmazásuk